Fluticasone Propionate 10% Nasal Insert not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Chronic Allergic Rhinitis
- Main trialPhase 1
- “Phase 1 study designed to evaluate the safety, tolerability and Pharmacokinetic (PK) of a fluticasone propionate (FP) 10% nasal insert in adults suffering from persistent allergic rhinitis. The nasal insert is intended to deliver FP locally. The study will consist of a 4-week treatment period (Main Phase) followed by a 22-week follow-up period (Extension Phase).”In the company’s words, NCT07918404 on ClinicalTrials.gov
Coming up1
- Nov 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Nov 2027 | Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026